(2S)-2-(butylsulfonylamino)-3-(4-hydroxyphenyl)propanoic acid

We are (2S)-2-(butylsulfonylamino)-3-(4-hydroxyphenyl)propanoic acid CAS:149490-60-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   (2S)-2-(butylsulfonylamino)-3-(4-hydroxyphenyl)propanoic acid
CAS.NO:149490-60-8
Synonyms:
N-(Butylsulfonyl)-L-tyrosine
L-N-Butylsulfonyl-p-hydroxyphenylalanine
(S)-2-(butylsulfonamido)-3-(4-hydroxyphenyl)propanoic acid

Molecular Formula:C13H19NO5S
Molecular Weight:301.35900

Physical and Chemical Properties:
Density: 1.321g / cm3
Boiling point: 519.6ºC at 760mmHg
Melting point: /
Flash point: 268ºC
Refractive index: 1.57

Specification:
Appearance:  Yellowish to yellow powder
Purity:≥99%
Impurity: <0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Tirofiban Hydrochloride CAS:142373-60-2

Related News: We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries.4-Hydroxycarbazole China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.(2S)-propane-1,2-diamine,dihydrochloride CAS:19777-66-3 China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.446-11-7 China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.Pharmaceutical intermediates and APIs belong to the fine chemical industry.